Eventide Asset Management LLC Sells 4,150 Shares of argenex SE $ARGX

Eventide Asset Management LLC decreased its stake in shares of argenex SE (NASDAQ:ARGX) by 3.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 121,221 shares of the company’s stock after selling 4,150 shares during the period. argenex comprises about 1.6% of Eventide Asset Management LLC’s holdings, making the stock its 11th biggest position. Eventide Asset Management LLC’s holdings in argenex were worth $101,938,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Abound Wealth Management boosted its position in shares of argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC bought a new position in shares of argenex during the fourth quarter worth $28,000. Ameriflex Group Inc. bought a new position in shares of argenex during the third quarter worth $32,000. Sunbelt Securities Inc. bought a new position in shares of argenex during the third quarter worth $36,000. Finally, Aventura Private Wealth LLC bought a new position in shares of argenex during the fourth quarter worth $38,000. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Oppenheimer dropped their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. HC Wainwright upped their target price on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Citizens Jmp upped their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Finally, Robert W. Baird upped their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Trading Down 0.6%

Shares of ARGX opened at $893.52 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market cap of $55.57 billion, a P/E ratio of 39.78, a P/E/G ratio of 1.37 and a beta of 0.47. The company’s fifty day simple moving average is $812.09 and its 200-day simple moving average is $812.17.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The business had revenue of $1.31 billion for the quarter. Analysts predict that argenex SE will post 26.19 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.